SXTP
60 Degrees Pharmaceuticals, Inc
$1.54
-2.53%
2026-05-08
About 60 Degrees Pharmaceuticals, Inc
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
Key Fundamentals
Forward P/E
-0.20
EPS (TTM)
$-11.73
ROE
-200.9%
Revenue Growth (YoY)
16.2%
Profit Margin
0.0%
Debt/Equity
4.52
Beta
2.70
Market Cap
$4.2M
Avg Volume (10D)
46K
Recent Breakout Signals
No recent breakout signals detected for SXTP.
Recent Price Range (60 Days)
60D High
$4.19
60D Low
$1.29
Avg Volume
1.2M
Latest Close
$1.54
Get breakout alerts for SXTP
Sign up for Breakout Scanner to receive daily notifications when SXTP triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
60 Degrees Pharmaceuticals, Inc (SXTP) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SXTP daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SXTP operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.